KR101459530B1 - 폭스바이러스 감염의 치료 방법 - Google Patents

폭스바이러스 감염의 치료 방법 Download PDF

Info

Publication number
KR101459530B1
KR101459530B1 KR1020127007710A KR20127007710A KR101459530B1 KR 101459530 B1 KR101459530 B1 KR 101459530B1 KR 1020127007710 A KR1020127007710 A KR 1020127007710A KR 20127007710 A KR20127007710 A KR 20127007710A KR 101459530 B1 KR101459530 B1 KR 101459530B1
Authority
KR
South Korea
Prior art keywords
virus
pharmaceutical composition
substituted
alkyl group
group
Prior art date
Application number
KR1020127007710A
Other languages
English (en)
Korean (ko)
Other versions
KR20120048697A (ko
Inventor
어반 람스테트
브레넌 클로제
니콜레 지츠만
레이몬드 에이. 드웩
테리 디. 버터스
Original Assignee
유나이티드 세러퓨틱스 코오포레이션
더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유나이티드 세러퓨틱스 코오포레이션, 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 filed Critical 유나이티드 세러퓨틱스 코오포레이션
Publication of KR20120048697A publication Critical patent/KR20120048697A/ko
Application granted granted Critical
Publication of KR101459530B1 publication Critical patent/KR101459530B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C07D307/48—Furfural

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127007710A 2009-09-04 2010-09-01 폭스바이러스 감염의 치료 방법 KR101459530B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27225209P 2009-09-04 2009-09-04
US61/272,252 2009-09-04
PCT/US2010/047498 WO2011028781A1 (en) 2009-09-04 2010-09-01 Methods of treating poxviral infections

Publications (2)

Publication Number Publication Date
KR20120048697A KR20120048697A (ko) 2012-05-15
KR101459530B1 true KR101459530B1 (ko) 2014-11-07

Family

ID=43649619

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007710A KR101459530B1 (ko) 2009-09-04 2010-09-01 폭스바이러스 감염의 치료 방법

Country Status (9)

Country Link
US (2) US20110065753A1 (US20110065753A1-20110317-C00005.png)
EP (1) EP2473493B1 (US20110065753A1-20110317-C00005.png)
JP (1) JP5575246B2 (US20110065753A1-20110317-C00005.png)
KR (1) KR101459530B1 (US20110065753A1-20110317-C00005.png)
CN (1) CN102625801B (US20110065753A1-20110317-C00005.png)
CA (1) CA2772807A1 (US20110065753A1-20110317-C00005.png)
ES (1) ES2485623T3 (US20110065753A1-20110317-C00005.png)
HK (1) HK1173723A1 (US20110065753A1-20110317-C00005.png)
WO (1) WO2011028781A1 (US20110065753A1-20110317-C00005.png)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655746B (zh) 2009-02-23 2016-08-03 联合治疗公司 亚氨基糖以及治疗病毒性疾病的方法
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
JP2016513729A (ja) * 2013-03-15 2016-05-16 ユニザー ヴィロロジー，エルエルシー 抗菌化合物
EP3046558B1 (en) 2013-09-16 2019-08-14 Emergent Virology LLC Deoxynojirimycin derivatives and methods of their using
BR112017008898B1 (pt) 2014-11-05 2022-11-29 Emergent Virology Llc Compostos de iminoaçúcares, suas composições farmacêuticas e usos dos mesmos para tratar doenças virais
WO2017201030A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating viral infection
US10176965B1 (en) * 2017-07-05 2019-01-08 ICT Integrated Circuit Testing Gesellschaft für Halbleiterprüftechnik mbH Aberration-corrected multibeam source, charged particle beam device and method of imaging or illuminating a specimen with an array of primary charged particle beamlets

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077427A2 (en) * 2005-01-21 2006-07-27 Mnl Pharma Limited Antiviral drug combinations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2834122A1 (de) * 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2839309A1 (de) * 1978-09-09 1980-03-27 Bayer Ag 3,4,5-trihydroxypiperidin-derivate
DE2853573A1 (de) * 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3611841A1 (de) * 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
DE3814549A1 (de) * 1987-10-30 1989-05-18 Bayer Ag N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
US5144037A (en) * 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US5103008A (en) * 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
CA2312423A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) * 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9828474D0 (en) * 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
EP1165080A2 (en) * 1999-02-12 2002-01-02 G.D. SEARLE & CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
WO2001007078A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
ES2686775T3 (es) * 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
EP2058004A1 (en) * 2005-03-16 2009-05-13 University of Oxford Mannose immunogens for HIV-1
EP3441090A1 (en) * 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
KR20080033463A (ko) * 2005-07-27 2008-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도
BRPI0615974A2 (pt) * 2005-07-27 2011-05-31 Univ Florida uso de choque térmico para tratar uma doença ocular em um indivìduo, método para recrutar uma célula-tronco para um tecido ocular de um indivìduo com necessidade da mesma, uso de choque térmico para tratar uma doença ou um distúrbio ocular em um indivìduo com necessidade do mesmo, uso de choque térmico para regenerar a retina em um indivìduo com necessidade do mesmo, uso de choque térmico para reparar os danos ao epitélio pgmentar da retina em um indivìduo com necessidade do mesmo, uso de choque térmico para tratar a degeneração macular em um indivìduo com necessidade do mesmo, composição farmacêutica para o recrutamento de células-tronco, composição farmacêutica para recrutamento de células-tronco em um tecido ocular, kit e método para identificar um agente que aumenta o recrutamento de células-tronco em um tecido ocular
US20070244184A1 (en) * 2006-01-09 2007-10-18 Simon Fraser University Glycosidase inhibitors and methods of synthesizing same
CA2650311A1 (en) * 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
US8975280B2 (en) * 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
JP2011518124A (ja) * 2008-03-26 2011-06-23 ユニバーシティ・オブ・オックスフォード 小胞体ターゲッティングリポソーム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077427A2 (en) * 2005-01-21 2006-07-27 Mnl Pharma Limited Antiviral drug combinations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ChemBioChem. Vol. 10, Issue. 6, pp.1101-1105 *
ChemBioChem. Vol. 10, Issue. 6, pp.1101-1105*

Also Published As

Publication number Publication date
US20160243097A1 (en) 2016-08-25
JP5575246B2 (ja) 2014-08-20
US20110065753A1 (en) 2011-03-17
CN102625801A (zh) 2012-08-01
CN102625801B (zh) 2015-09-09
CA2772807A1 (en) 2011-03-10
EP2473493B1 (en) 2014-04-30
HK1173723A1 (en) 2013-05-24
EP2473493A4 (en) 2013-01-09
ES2485623T3 (es) 2014-08-13
EP2473493A1 (en) 2012-07-11
JP2013503882A (ja) 2013-02-04
WO2011028781A1 (en) 2011-03-10
KR20120048697A (ko) 2012-05-15

Similar Documents

Publication Publication Date Title
KR101459530B1 (ko) 폭스바이러스 감염의 치료 방법
US9943532B2 (en) Iminosugars and methods of treating viral diseases
JP5752689B2 (ja) フィロウイルス疾患を治療するイミノ糖および方法
EP2440205B1 (en) Iminosugars for use in the treatment of bunyaviral and togaviral diseases
KR101497194B1 (ko) 오르토믹소바이러스 감염의 치료 방법
KR101787434B1 (ko) 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee